ArticleCytotechnology2000
Survival of 3T3 cells expressing or co-expressing bFGF and/or IGF-I and/or IGF-II in low serum and serum free media.
Article in Cytotechnology, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this study was to improve the survival ofNIH3T3 cells in low serum or serum-free media by theendogenous expression of recombinant bFGF (basicfibroblast growth factor) and/or IGF (insulin-likegrowth factor) -I and II. Expression was detected byWestern blotting, and the growth characteristics ofdifferent transfected cell lines investigated in bothserum-free and low serum conditions and also in softagar. Morphological changes and the growth rate werecompared with growth in normal serum-containingmedium. The experimental data suggested that theexpression of either bFGF alone, or the co-expressionof bFGF and either IGF-I or II could improve thesurvival of NIH3T3 cells in low serum or serum-freemedia. The use of such lines could decrease the use ofserum in cell culture and thus both reduce the costsinvolved in this technique and simplify thedown-stream purification procedure in protein harvest.Hence, such lines may be of value in both experimentaland industrial applications.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.